Pregenerate Inc.

Pregenerate is a biotechnology startup focused on revolutionizing osteoarthritis treatment. Founded in 2019 and based in Austria, the company aims to replace expensive and inefficient animal testing in medical and pharmaceutical research. Pregenerate's products and services utilize scaleable organ-on-a-chip models to advance pharmaceutical research for arthritis treatments. By employing human cells in their model, the company helps pharmaceutical companies save billions of dollars and improve the success rates of their drugs to market. In June 2022, Pregenerate secured a Convertible Note investment from SOSV, signaling investor confidence in the company's innovative approach to addressing the global degenerative joint disease, osteoarthritis. This technology not only has the potential to impact the aging human population but also sport horses and companion animals, and in the long run, it could enable personalized treatment for arthritis patients, emphasizing the company's potential for growth and impact in the Life Sciences and Medical Devices industries.